OR WAIT null SECS
The company has formed an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s COVID-19 vaccine candidate, to the people of Singapore.
Moderna announced on Dec. 14, 2020 that it has formed an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s COVID-19 vaccine candidate, to secure access to a COVID-19 vaccine for the people of Singapore.
The agreement comes after positive results from a Phase III study that showed efficacy of 94.1% against COVID-19 and 100% against severe COVID-19, Moderna said in a company press release.
“We appreciate the confidence the Ministry of Health of Singapore has demonstrated in our mRNA vaccine platform by including mRNA-1273 in their portfolio of vaccines. We recognize that addressing this global pandemic will require a number of vaccines and therapeutic options, and we are proud of the role Moderna has been able to play in this global effort,” said Stéphane Bancel, Moderna’s CEO, in the press release. “We continue to advance the clinical development of mRNA-1273, and the recent positive primary efficacy analysis from our Phase III COVE study is an encouraging step forward as we work together to address this global health emergency by delivering a vaccine to the people of Singapore and around the world.”